The Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Positive bacterial growth
研究概览
简要总结
This study aimed to assess effectiveness of a taurolidine based lock solution in preventing the infections of central venous catheter (CVC) in intensive care unit (ICU) cases.
详细描述
The central venous catheter (CVC) is highly frequent in the intensive care unit (ICU), with an average use rate between 32% and 80% among adult ICU patients. The utilization of CVC in ICUs has escalated over the past decade, accompanied by a corresponding increase in problems related to their usage.
Taurolidine is a nontoxic substance having antibacterial impacts counter to mutually gram-positive and -negative bacteria, additionally to fungus. It decreases biofilm development and doesn't develop resistance to antibiotics, since it serves as an antiseptic rather than an antibiotic Consequently, it may function as a locking mechanism.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 21 years.
- •Both genders.
- •Patients admitted to the intensive care unit (ICU) requiring central venous catheter insertion.
排除标准
- •Cases with active infections, hemorrhage or bleeding disorders, infections within insertion place.
- •History of allergy to taurolidine, tigecycline, heparin, and citrate.
研究组 & 干预措施
Group I
Central venous catheters (CVCs) were locked with 2ml saline as a control group.
干预措施: Saline (Drug)
Group II
Central venous catheters (CVCs) were locked with 2ml of a solution comprising tigecycline 5mg/ml and heparin 500 IU/ml.
干预措施: Tigecycline and heparin (Drug)
Group III
Central venous catheters (CVCs) were locked with 2ml of a solution containing taurolidine-citrate-heparin (1.35% taurolidine, 4% citrate, and 500 IU/ml heparin).
干预措施: Taurolidine-citrate-heparin (Drug)
结局指标
主要结局
Positive bacterial growth
时间窗: 30 days after the procedure
Positive bacterial growth of a swab was recorded.
次要结局
- Assessment of catheter-related bloodstream infection(30 days after the procedure)
- Assessment of central venous catheter infection(30 days after the procedure)
- Lenght of intensive care unit stay(30 days after the procedure)
- Incidence of mortality(30 days after the procedure)
研究者
Doaa Kelany Zakaria Ibrahim
Assistant Lecturer of Anesthesiology, Intensive Care and Pain Medicine, Tanta University, Tanta, Egypt.
Tanta University